CASC
Cascadian Therapeutics, Inc.
CASC
CASC
Delisted
CASC was delisted on the 8th of March, 2018.
63 hedge funds and large institutions have $62.8M invested in Cascadian Therapeutics, Inc. in 2013 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 22 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
63
Holders Change
-3
Holders Change %
-4.55%
% of All Funds
2.04%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
12
Increased
14
Reduced
22
Closed
14
Calls
$4.04M
Puts
$874K
Net Calls
+$3.17M
Net Calls Change
+$275K
Top Buyers
| 1 |
QF
1
QVT Financial
New York
|
$7.96M |
| 2 |
2
First Eagle Investment Management
New York
|
$4.69M |
| 3 |
BI
3
BVF Inc
San Francisco,
California
|
$18.3M |
| 4 |
SM
4
Sabby Management
Miami Beach,
Florida
|
$1.36M |
| 5 |
PC
5
PointState Capital
New York
|
$1.03M |
Top Sellers
| 1 |
1
JPMorgan Chase & Co
New York
|
$51K |
| 2 |
2
Millennium Management
New York
|
$824K |
| 3 |
3
Northern Trust
Chicago,
Illinois
|
$181K |
| 4 |
4
Morgan Stanley
New York
|
$224K |
| 5 |
5
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
$1.16M |
